Antimicrobial activities of trimethoprim/sulfamethoxazole, 5-iodo-2′-deoxyuridine and rifampicin against Staphylococcus aureus

被引:23
作者
Zander, Johannes [1 ]
Besier, Silke [1 ]
Faetke, Sebastian [1 ]
Saum, Stephan H. [2 ]
Mueller, Volker [2 ]
Wichelhaus, Thomas A. [1 ]
机构
[1] Hosp Goethe Univ, Inst Med Microbiol & Infect Control, D-60596 Frankfurt, Germany
[2] Goethe Univ Frankfurt, Inst Mol Biosci, D-60438 Frankfurt, Germany
关键词
Rifampicin; Trimethoprim/sulfamethoxazole; 5-Iodo-2 '-deoxyuridine; Antimicrobial activity; Thymidine; FIBROSIS LUNG-DISEASE; SMALL-COLONY VARIANTS; CYSTIC-FIBROSIS; TRIMETHOPRIM; ANTAGONISTS; INFECTIONS; MANAGEMENT; COMMUNITY; ANALOGS;
D O I
10.1016/j.ijantimicag.2010.08.007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Trimethoprim/sulfamethoxazole (SXT), alone and in combination with rifampicin (RIF), is a therapeutic option against Staphylococcus aureus, including strains expressing meticillin resistance. However, the antimicrobial activity of SXT is antagonised by thymidine, which can be present in infected and/or inflamed tissues such as the airways of cystic fibrosis (CF) patients. In this study, thymidine concentrations in CF sputa were determined and the antimicrobial activities of SXT, 5-iodo-2'-deoxyuridine (IdUrd) and RIF alone and in combination against S. aureus were analysed. Thymidine concentrations in the sputa of ten different CF patients varied from < 100 mu g/L to 38 845 mu g/L. The abolished antimicrobial activity of SXT against 22 S. aureus strains in the presence of thymidine was restored by combination with IdUrd. In contrast, SXT combined with RIF in the presence of thymidine did not show a synergistic effect and, furthermore, allowed the emergence of RIF-resistant bacteria. Adding RIF to the combination of SXT and IdUrd did not improve antimicrobial activity against S. aureus. In conclusion, the combination of SXT and RIF as a therapeutic option against S. aureus infections in chronic inflamed tissues should be judged critically. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:562 / 565
页数:4
相关论文
共 15 条
[1]  
ALVAREZ S, 1982, REV INFECT DIS, V4, P390
[2]  
[Anonymous], 1999, M26AE CLSI
[3]   Thymidine-Dependent Staphylococcus aureus Small-Colony Variants: Human Pathogens That Are Relevant Not Only in Cases of Cystic Fibrosis Lung Disease [J].
Besier, Silke ;
Zander, Johannes ;
Siegel, Ekkehard ;
Saum, Stephan H. ;
Hunfeld, Klaus-Peter ;
Ehrhart, Annabelle ;
Brade, Volker ;
Wichelhaus, Thomas A. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (11) :3829-3832
[4]   Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease [J].
Besier, Silke ;
Smaczny, Christina ;
von Mallinckrodt, Christian ;
Krahl, Andreas ;
Ackermann, Hanns ;
Brade, Volker ;
Wichelhaus, Thomas A. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (01) :168-172
[5]  
CLSI, 2012, CLSI DOCUMENT M07 A9, V9th
[6]   Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections [J].
Ellis, MW ;
Lewis, JS .
CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (06) :496-501
[7]   Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2′-deoxyuridine (IdUrd) [J].
Galanis, E ;
Goldberg, R ;
Reid, J ;
Atherton, P ;
Sloan, J ;
Pitot, H ;
Rubin, J ;
Adjei, AA ;
Burch, P ;
Safgren, SL ;
Witzig, TE ;
Ames, MM ;
Erlichman, C .
ANNALS OF ONCOLOGY, 2001, 12 (05) :701-707
[8]  
GRUENEBERG RN, 1980, J ANTIMICROB CHEMOTH, V6, P349
[9]   ANTAGONISTIC INTERACTION OF RIFAMPICIN AND TRIMETHOPRIM [J].
HARVEY, RJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1978, 4 (04) :315-327
[10]   Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus [J].
Kaka, Anjum S. ;
Rueda, Adriana M. ;
Shelburne, Samuel A., III ;
Hulten, Kristina ;
Hamill, Richard J. ;
Musher, Daniel M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (03) :680-683